REG - ReNeuron Group plc - Grant of Options
15/07/2022 07:00
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220715:nRSO5685Sa&default-theme=true
RNS Number : 5685S ReNeuron Group plc 15 July 2022
ReNeuron Group plc
("ReNeuron" or "the Company" or "the Group")
Grant of Options
ReNeuron Group plc (AIM: RENE), a UK based leader in stem cell derived exosome
technologies, announces that grants were made on 14 July 2022 for options over
Ordinary Shares of 1p each ("Options") under the terms of the Company's Long
Term Incentive Plan, Consultant Option Agreement (together "The Plans") and
its Non-Executive Share Option Scheme. The grants made to Directors and
Persons Discharging managerial Responsibilities (PDMRs) are listed below.
The Options granted under The Plans have an exercise price of 31.5 pence per
share, being the closing mid-market price of the Company's shares on 13 July
2022. The Options vest in equal proportions at 12, 24 and 36 months from the
date of grant. None of the Options are subject to the achievement of
performance conditions.
The Options granted to Iain Ross are granted under the Non-Executive Share
Option Scheme. The Options are granted with an exercise price of 31.5 pence
per share without performance conditions and vest monthly over three years on
a straight-line basis.
Name Title Date of grant of Options Number of Options granted (i) Total shares over which options are held (post award) Percentage of issued shares under option
Iain Ross Executive Chairman 14 July 2022 300,000 500,000 0.88%
Catherine Isted Chief Financial Officer 14 July 2022 650,000 1,114,136 1.95%
Stefano Pluchino Chief Scientific Officer 14 July 2022 100,000 100,000 0.18%
Randolph Corteling VP of Research 14 July 2022 500,000 500,000 0.88%
Suzanne Hancock Head of Operations 14 July 2022 250,000 349,326 0.61%
ENDS
Enquiries:
ReNeuron www.reneuron.com/investors (http://www.reneuron.com/investors)
Iain Ross, Chairman Via Walbrook PR
Catherine Isted, Chief Financial Officer
Liberum Capital Limited (NOMAD and Joint Broker) +44 (0)20 3110 2000
Phil Walker (Investment Banking)
Richard Lindley (Investment Banking)
Ben Cryer (Investment Banking)
Allenby Capital Limited (Joint Broker) +44 (0)20 3328 5656
James Reeve/George Payne (Corporate Finance)
Stefano Aquilino (Sales & Corporate Broking)
Walbrook PR (Media & Investor Relations) +44 (0)20 7933 8780 or reneuron@walbrookpr.com
(mailto:reneuron@walbrookpr.com)
Paul McManus / Alice Woodings +44 (0)7980 541 893 / +44 (0)7407 804 654
About ReNeuron
ReNeuron is a UK based leader in proprietary stem cell derived exosome
technologies, harnessing its unique stem cell technologies to develop 'off the
shelf' treatments for diseases with significant unmet needs.
ReNeuron's stem cell derived proprietary exosome technology platform offers a
delivery mechanism for a variety of payloads such as siRNA, mRNA, proteins,
small molecules and genes. The Group has a growing number of partner
collaborations with Global Pharma, Biotech and academic partners in this
fast-expanding area of scientific and commercial interest. ReNeuron also has
the ability, through its conditionally immortalised induced pluripotent stem
cell (iPSC) platform, to make allogeneic tissue cells of choice and has the
potential to produce exosomes with tissue specific targeting ability.
The Group has out-licenced its CTX Programme for stroke disability and hRPC
programme in retinitis pigmentosa to Fosun in China and is looking to
out-license both of these programmes in other territories.
ReNeuron's shares are traded on the London AIM market under the symbol RENE.L.
For further information visit www.reneuron.com (http://www.reneuron.com)
Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them
(Disclosure in relation to grant of share options to Directors and PDMRs)
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Iain Ross
2 Reason for the notification
a) Position/status Executive Chairman
b) Initial notification /Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name ReNeuron Group plc
b) LEI 2138003TU12CQ5TZO137
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument Ordinary Shares 1p
Identification code RENE - GB00BF5G6K95
b) Nature of the transaction Grant of share options
c) Price(s) and volume(s) Price(s) Volume(s)
31.5p 300,000
d) Aggregated information N/A
e) Date of the transaction 14 July 2022
f) Place of the transaction Outside of a trading venue
d)
Aggregated information
N/A
e)
Date of the transaction
14 July 2022
f)
Place of the transaction
Outside of a trading venue
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Catherine Isted
2 Reason for the notification
a) Position/status Chief Financial Officer
b) Initial notification /Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name ReNeuron Group plc
b) LEI 2138003TU12CQ5TZO137
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument Ordinary Shares 1p
Identification code RENE - GB00BF5G6K95
b) Nature of the transaction Grant of share options
c) Price(s) and volume(s) Price(s) Volume(s)
31.5p 650,000
d) Aggregated information N/A
e) Date of the transaction 14 July 2022
f) Place of the transaction Outside of a trading venue
d)
Aggregated information
N/A
e)
Date of the transaction
14 July 2022
f)
Place of the transaction
Outside of a trading venue
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Stefano Pluchino
2 Reason for the notification
a) Position/status Chief Scientific Officer
b) Initial notification /Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name ReNeuron Group plc
b) LEI 2138003TU12CQ5TZO137
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument Ordinary Shares 1p
Identification code RENE - GB00BF5G6K95
b) Nature of the transaction Grant of share options
c) Price(s) and volume(s) Price(s) Volume(s)
31.5p 100,000
d) Aggregated information N/A
e) Date of the transaction 14 July 2022
f) Place of the transaction Outside of a trading venue
d)
Aggregated information
N/A
e)
Date of the transaction
14 July 2022
f)
Place of the transaction
Outside of a trading venue
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Randolph Corteling
2 Reason for the notification
a) Position/status VP of Research
b) Initial notification /Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name ReNeuron Group plc
b) LEI 2138003TU12CQ5TZO137
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument Ordinary Shares 1p
Identification code RENE - GB00BF5G6K95
b) Nature of the transaction Grant of share options
c) Price(s) and volume(s) Price(s) Volume(s)
31.5p 500,000
d) Aggregated information N/A
e) Date of the transaction 14 July 2022
f) Place of the transaction Outside of a trading venue
d)
Aggregated information
N/A
e)
Date of the transaction
14 July 2022
f)
Place of the transaction
Outside of a trading venue
1 Details of the person discharging managerial responsibilities / person closely
associated
a) Name Suzanne Hancock
2 Reason for the notification
a) Position/status Head of Operations
b) Initial notification /Amendment Initial notification
3 Details of the issuer, emission allowance market participant, auction
platform, auctioneer or auction monitor
a) Name ReNeuron Group plc
b) LEI 2138003TU12CQ5TZO137
4 Details of the transaction(s): section to be repeated for (i) each type of
instrument; (ii) each type of transaction; (iii) each date; and (iv) each
place where transactions have been conducted
a) Description of the financial instrument, type of instrument Ordinary Shares 1p
Identification code RENE - GB00BF5G6K95
b) Nature of the transaction Grant of share options
c) Price(s) and volume(s) Price(s) Volume(s)
31.5p 250,000
d) Aggregated information N/A
e) Date of the transaction 14 July 2022
f) Place of the transaction Outside of a trading venue
d)
Aggregated information
N/A
e)
Date of the transaction
14 July 2022
f)
Place of the transaction
Outside of a trading venue
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
or visit
www.rns.com (http://www.rns.com/)
.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
. END DSHDZLFFLDLXBBBRecent news on ReNeuron
See all newsREG - AIM ReNeuron Group plc - Cancellation - ReNeuron Group Plc
AnnouncementREG - ReNeuron Group plc - Corporate update and AIM cancellation
AnnouncementREG - ReNeuron Group plc - Corporate Update
AnnouncementREG - ReNeuron Group plc - Change of Registered Address
AnnouncementREG - ReNeuron Group plc - Creditor’s decision on Administrators' Proposals
Announcement